Skip to main content
SpringerLink
Log in

Response to Naunton and Duyvendak re “Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk?”

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wood D, De Backer G, Faergeman O et al (1998) Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Atherosclerosis 140:199–270

    Article  PubMed  CAS  Google Scholar 

  2. Steering Committee of the Physicians’ Health Study Research Group (1989) Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 321:129–135

    Article  Google Scholar 

  3. The Medical Research Council’s General Practice Research Framework (1998) Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351:233–241

    Article  Google Scholar 

  4. Hanson L, Zanchetti A, Carruthers SG et al (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755–1762

    Article  Google Scholar 

  5. U.S. Preventive Services Task Force (2002) Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 136:157–160

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto di Ricerche Farmacologiche “Mario Negri”, Via Eritrea 62, 20157, Milan, Italy

    Lara Monesi, Fausto Avanzini & Maria Carla Roncaglioni

Authors
  1. Lara Monesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fausto Avanzini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Carla Roncaglioni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Carla Roncaglioni.

Additional information

on behalf of the Collaborative Group Risk and Prevention Study

Rights and permissions

Reprints and permissions

About this article

Cite this article

Monesi, L., Avanzini, F. & Roncaglioni, M.C. Response to Naunton and Duyvendak re “Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk?”. Eur J Clin Pharmacol 62, 79–80 (2006). https://doi.org/10.1007/s00228-005-0048-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-005-0048-0

Keywords

Search

Navigation